New Analyses Demonstrate Versatility and Continued Efficacy

/PRNewswire/ -- Johnson & Johnson announced today an analysis from the Phase 1/2 MonumenTAL-1 study of TALVEY™ (talquetamab-tgvs) in patients with relapsed or...

Related Keywords

United States , California , San Francisco , American , Christie Corbett , Satu Glawe , Christoph Heuck , American Society Of Hematology , None Of Janssen Research Development , Hematology Clinical Development , Johnson , European Commission , Janssen Research Development , Eastern Cooperative Oncology Group , Janssen Biotech Inc , University Of California , Myeloma Program , International Myeloma Working Group , Exchange Commission , Annual Meeting , Ajai Chari , Multiple Myeloma Program , Clinical Medicine , Pivotal Phase , Highlight Reported Continued Efficacy , Reduced Intensity , Vice President , Johnson Innovative , Independent Review Committee , Multiple Myeloma , Risk Evaluation , Mitigation Strategy , Release Syndrome , Weight Loss , Fetal Toxicity , Boxed Warning , Innovative Medicine , Janssen Research , Janssen Biotech , Private Securities Litigation Reform Act , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Johnson Amp , Biotechnology , Health Care Amp Hospitals , Medical Pharmaceuticals , Pharmaceuticals , Clinical Trials Amp Medical Discoveries ,